| Net loss per share |
Note 14 –
Net loss per share
The
following tables sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the three
and six months ended June 30, 2026 and 2025 (in thousands, except per share amounts):
| Schedule of basic and diluted net loss per share | |
| | | |
| | | |
| | | |
| | |
| | |
Three Months Ended
June 30, | | |
Six Months Ended
June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Numerator – basic & diluted: | |
| | | |
| | | |
| | | |
| | |
| Net loss attributable to common stockholders, basic and diluted | |
$ | (17,453 | ) | |
$ | (11,967 | ) | |
$ | (34,527 | ) | |
$ | (22,522 | ) |
| Denominator: | |
| | | |
| | | |
| | | |
| | |
| Weighted-average number of shares outstanding, basic and diluted | |
| 49,236,129 | | |
| 39,586,205 | | |
| 47,148,836 | | |
| 38,426,604 | |
| Net loss per share attributable to common stockholders, basic and diluted | |
$ | (0.35 | ) | |
$ | (0.30 | ) | |
$ | (0.73 | ) | |
$ | (0.59 | ) |
The
following potentially dilutive shares have been excluded from the computation of diluted weighted-average shares outstanding because
such securities have an antidilutive impact due to the Company’s net loss:
| Schedule of anti-dilutive shares | |
| | | |
| | |
| | |
June 30, | |
| | |
2026 | | |
2025 | |
| Outstanding warrants | |
| 1,944,214 | | |
| 1,978,938 | |
| Outstanding stock options | |
| 5,944,485 | | |
| 4,684,314 | |
| Total dilutive shares | |
| 7,888,699 | | |
| 6,663,252 | |
|